An HPLC-peroxyoxalate chemiluminescence (PO-CL) method for simultaneous determination of methylphenidate (MPH) and ritalinic acid (RA) was developed.
Introduction
Methylphenidate (MPH), a phenethylamine derivative, is a well-known medicament for attention-deficit hyperactivity disorder and narcolepsy [1] . It is known that there is marked individual variability in the dose-response relationship for MPH, and therefore dosage must be titrated for optimal effect and avoidance of toxicity in each patient [2, 3] .
However, it is unclear whether this variability is predominantly pharmacokinetic or pharmacodynamic. MPH is reported to be absorbed rapidly and completely from the intestine after oral administration and hydrolyzed at the methyl ester moiety to its main metabolite, ritalinic acid (RA) [4] . And in human carboxylesterase contributes to hydrolyze MPH stereo-selectively to RA [5] . In order to fully assess the processes associated with metabolic clearance, simultaneous determination of MPH and RA might be needed, though RA is a major inactive metabolite.
Due to its similar pharmacological effect of amphetamine, MPH has been illicitly abused [2, 6] . Recent fatalities due to the abuse of MPH have been reported [6] . To distinguish MPH abuse from external contamination of sample by MPH, identification of MPH and its metabolite in the sample was simultaneously required. Therefore, a simple and reliable analytical method to determine MPH and RA is in requisite, due to their clinical and forensic interests described above. However, only a few methods for simultaneous determination of MPH and RA in biological samples have been reported [7] [8] [9] . Chromatographic behavior between MPH and RA is different, because polarity of RA is higher than that of MPH. This is one of reasons for difficulty on simultaneous determination of MPH and RA.
Several analytical methods have been reported for the determination of MPH and/or RA in biological matrices. Gas chromatography-mass spectrometry [10, 11] , HPLC-UV [12] [13] [14] , -fluorescence (-FL) detections [15] , liquid chromatography (LC-MS) [5, [7] [8] [9] 16, 17] and LC-tandem mass spectrometry (LC-MS/MS) [2, 18, 19] methods were widely used. Quite recently, MS detection for very low-level quantification of MPH in biological samples has been frequently used. However, the use of MS detector, which is large and expensive equipment, is restricted. Simultaneous determination of MPH and RA by FL detection with nano-g level of sensitivity has never been achieved previously.
On the other hand, a peroxyoxalate chemiluminescence (PO-CL) method, which is a powerful tool to determine fluorophore, has been used to determine trace amounts of biologically active compounds such as drugs in biological samples due to its high sensitivity and selectivity [20] . Thus sensitive determination of MPH and RA might be achieved by an HPLC-PO-CL method combined with FL labeling technique, although no previous achievement has been ever reported. In our previous study, we already developed a sensitive HPLC-PO-CL method for determination of MDMA-related compounds [21] .
In this study, an HPLC-PO-CL method for simultaneous determination of MPH and RA labeled with 4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F) was developed. To clean-up labeled sample, two types of solid-phase extraction (SPE) cartridges were used. Furthermore, the proposed method was applied to monitor MPH and RA after an administration of MPH to rat. Water was purified by passing through a Pure Line WL21P system (Yamato Scientific
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Co., Tokyo, Japan). A stock standard solution (1 mg/mL) of MPH and RA were prepared by dissolving in MeOH and stored at -30C until analysis.
Pretreatment of plasma sample
Fifty-L of plasma spiked with 10 L of IS in CH 3 CN were deprotenized with 500 L of CH 3 CN. After centrifugation (3500g) at 20 ℃ for 10 min, the resulted supernatant was dried-up and the residue was applied to labeling reaction with DBD-F.
Each 50-L of borate buffer (100 mM, pH 8.5) and 120 mM DBD-F in CH 3 CN were spiked to the residue, and heated at 80℃ for 30 min in the dark (Fig. 1) . The reaction mixture was cooled in ice-water to stop the reaction.
The reaction mixture with DBD-F was applied to SPE cartridges to eliminate the excess reagent and interfering materials for detection of MPH-and RA-DBD. 
HPLC conditions
The HPLC system for separation of MPH-and RA-DBD labels is shown in Fig 
Validation of the method
The standard of MPH and RA solutions spiked plasma were independently prepared adequate times in validation study. For determination of MPH and RA, calibration curves using rat plasma spiked with known concentration of standards prepared independently three times were prepared by the internal standard method. The IS solution containing standards were spiked to prepare the calibration curves. The calibration equations and correlation coefficients using the model of least squares were calculated by the software JMP ® 8.0.2 (SAS Institute Japan, Tokyo). Plasma samples spiked with MPH ranging from 10 to 1000 ng/mL plasma and RA ranging from 100 to 10000 ng/mL plasma were prepared. The limit of detection (LOD) and quantification (LOQ) were defined as a concentration given signal-to-noise (S/N) ratio of 3 and 10.
Recovery of the proposed method was expressed as the peak height ratio between standards spiked in plasma with SPE step and standards without clean-up with SPE.
Accuracy and precision for inter-day and intra-day assay were evaluated by using plasma samples spiked with 10, 50 and 500 ng/mL of MPH, and 100, 500 and 5000 ng/mL of RA, respectively. Data was expressed as mean±SD (n=6).
Pharmacokinetic study of MPH and RA
Wistar male rats (n=3, 280-300 g, Otsubo experimental animals, Nagasaki, Japan) were used. Rats were anesthetized with ethyl carbamate (1.5 g/kg) before cannulation. From This experiment was performed with an approval of Nagasaki University Animal
Care and Use Committee.
Results and discussion
Optimization of pretreatment conditions of sample
Labeling conditions such as DBD-F and borate buffer (pH 8.5) concentrations and reaction time were examined. 1.0 g/mL of MPH standard solution was used and its chemiluminescence intensity (CLI) and decomposition ratio to RA were evaluated. At first, the effects of DBD-F concentration (20-320 mM) on the CLI were examined.
DIB-MPH gave maximum CLI with 120 mM and decomposition ratio of MPH decreased with increase of DBD-F concentration, thus the following experiments were done using 120 mM DBD-F. Next, concentration of borate buffer ranging from 25 to 150 mM was examined, and maximum constant CLI was achieved using more than 75 mM of borate buffer with low decomposition ratio of MPH, thus 100 mM was selected.
Finally, reaction time at room temperature was studied in the range of 10-60 min. compounds were not mentioned clearly [7, 9] . And moderate recoveries (75% for MPH and 60% for RA) were obtained by LC-MS with SPE (Oasis HLB cartridge, Waters) [8] .
To improve recovery, further examination with other SPE cartridges should be needed.
HPLC and CL detection conditions
At first, the isocratic separation of MPH-and RA-DBD was attempted. Since chromatographic behavior of both labels on reversed phase column 
Validation of the proposed method
Calibration curves of MPH and RA obtained with spiked plasma were linear with r-values greater than 0.998 in the ranges of 10-1000 ng/mL and 100-10000 ng/mL.
Since concentration range of RA in plasma sample after administration might be 10 times higher than that of MPH, high concentrations for preparation of RA calibration curve were used. The LODs of MPH and RA at S/N ratio of 3 were 2.2 ng/mL (93.2 fmol on column) and 0.4 ng/mL (20.2 fmol on column), respectively, and the LOQs at S/N ratio of 10 were 7.3 ng/mL (MPH) and 1.3 ng/mL (RA).
Accuracy, intra-and inter-day precisions of the proposed method were evaluated by analyzing plasma spiked with known concentrations of MPH (10, 50 and 500 ng/mL) and RA (100, 500 and 5000 ng/mL) as shown in Table 1 . Accuracy in the range of 91.6±8.9%-108.9±2.4% was obtained. The intra-day RSDs for MPH and RA were 9.7 (10 ng/mL), 2.2 (50 ng/mL) and 3.6 % (500 ng/mL), and 6.2 (100 ng/mL), 3.1 (500 ng/mL) and 2.7 % (5000 ng/mL), respectively. Inter-day precision (RSDs) of 9.3 (10 ng/mL), 5.0 (50 ng/mL) and 8.7 % (500 ng/mL) for MPH were obtained, while those for RA were 7.0 (100 ng/mL), 6.1 (500 ng/mL) and 6.7 % (5000 ng/mL). By our method, decomposition of MPH to RA was not found. Because peak of RA did not appear when the plasma spiked with MPH was analyzed.
The sensitivity and plasma volume required for measurement of the proposed method and conventional methods were summarized in Table 2 . Plasma volume required for measurement in our method was comparable to those of the conventional methods [7] [8] [9] , though our method was less sensitive. The method reporting completed simultaneous determination of MPH and RA are rare. One of the reasons might be remarkable difference of chromatographic behavior of these compounds on reversed phase chromatography. To our knowledge, only LC-MS methods to determine MPH and RA simultaneously in plasma could be achieved [7] [8] [9] . The MS detection having excellent selectivity negotiates this difference on chromatographic behavior. In this study, the combination of fluorescence labeling of substances, clean-up step and gradient elution overcame it. Table 1   Table 2 Pharmacokinetic study of MPH and RA By using the proposed method MPH could be monitored after 480 min of administration. MPH was hydrolyzed to RA rapidly and this fact agrees with that in previous report [3] . The concentration of RA at 480 min after administration was kept high levels and 8 times higher than that of MPH. Pharmacokinetic parameters of MPH and RA was calculated and is summarized in Table 3 . The K (0.0046±0.0027 min -1 ) and CLR (0.025±0.009 L/min) of MPH obtained in this study were similar to those in previous report [3] . Kennerly et al., reported MPH is also metabolized to p-hydroxy methylphenidate in rat, but its concentration was lower than that of MPH [4] . In our study, no peak corresponding to p-hydroxy methylphenidate was found on the chromatogram. Applicability of the method could be clarified. Data was presented as mean±SD (n=3). Data was presented as mean±SD (n=6). Table 2 The sensitivity and plasma volume required of the proposed method and conventional methods 
